उत्पाद विवरण
1. Technical Specifications
| Attribute |
Details |
| Brand Name |
Daruvir-R Tablet |
| Generic Name |
Darunavir + Ritonavir |
| Strength |
Darunavir 600 mg + Ritonavir 100 mg per tablet |
| Dosage Form |
Oral Tablet |
| Packaging Size |
Commonly 60 tablets per bottle |
| Packaging Type |
HDPE bottle with child-resistant cap |
| Medicine Type |
Antiretroviral (Protease Inhibitor + Pharmacokinetic Booster) |
| Manufacturer |
Cipla Ltd. |
| Distributed By |
Authorized antiretroviral drug distributors / pharmacies |
2. Product Description
Daruvir-R Tablet is a fixed-dose combination of Darunavir (600 mg) and Ritonavir (100 mg).
-
Darunavir is a protease inhibitor that prevents HIV protease enzyme from cleaving viral polyproteins, leading to production of immature, non-infectious viral particles.
-
Ritonavir acts as a pharmacokinetic enhancer (booster) by inhibiting CYP3A4 metabolism, thereby increasing plasma concentration and efficacy of Darunavir.
It is indicated for the treatment of HIV-1 infection in adults and adolescents, usually in combination with other antiretroviral agents.
3. Product Highlights
| Attribute |
Details |
| Therapeutic Category |
Antiretroviral Protease Inhibitor Combination |
| Application Area |
Management of HIV-1 infection |
| Mechanism of Action |
Darunavir inhibits HIV-1 protease blocks viral replication; Ritonavir boosts Darunavir plasma levels by CYP3A4 inhibition |
| Administration |
Oral; usually one tablet twice daily with food (as per physicians prescription) |
| Storage Conditions |
Store at room temperature (below 30 C), protected from moisture & light |
4. Therapeutic Uses
-
HIV-1 Infection (in combination with other antiretrovirals):
-
Helps in reducing viral load and increasing CD4 cell counts, improving immune function.
5. Side Effects
Common:
Serious / Severe:
-
Severe skin reactions (Stevens-Johnson syndrome, TEN rare)
-
Hepatotoxicity (jaundice, elevated liver enzymes)
-
Hyperglycemia, insulin resistance
-
Lipid abnormalities (high cholesterol, triglycerides)
-
Pancreatitis (rare)
-
Cardiac conduction abnormalities (PR interval prolongation)
6. Precautions
-
Drug Interactions: Avoid concomitant use with drugs highly dependent on CYP3A4 (e.g., simvastatin, lovastatin, rifampicin, midazolam).
-
Liver Function: Monitor regularly; contraindicated in severe hepatic impairment.
-
Allergy: Contraindicated in patients with known hypersensitivity to sulfonamides (Darunavir has a sulfonamide moiety).
-
Pregnancy & Breastfeeding: Use with caution; breastfeeding not recommended in HIV-positive mothers.
-
Metabolic Monitoring: Monitor blood glucose and lipid profile during long-term therapy.
-
Adherence: Must be taken consistently with food for optimal absorption and to prevent resistance.